Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
Enovis (NYSE:ENOV) reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.
On the company’s first-quarter earnings call, Chief Execu
What Happened? Shares of medical technology company Enovis Corporation (NYSE:ENOV) jumped 7.6% in the afternoon session after the company reported better-tha...
Medical technology company Enovis Corporation (NYSE:ENOV) announced better-than-expected revenue in Q1 CY2026, with sales up 5.4% year on year to $589.2 mill...
Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Medical technology company Enovis Corporation (NYSE:ENOV) will be reporting earnings this Thursday before market hours. Here’s what to expect. Enovis missed ...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Enovis’s stock price has taken a beating over the past six months, shedding 26.8% of its value and falling to $23.41 per share. This might have investors con...
Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - specialty stocks fared in Q4, starting with Enovis (NYSE:ENOV).
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Shares of medical technology company Enovis Corporation (NYSE:ENOV) jumped 12.6% in the morning session after the company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. While the company's revenue of about $576 million for the quarter fell short of expectations, its adjusted earnings per share of $0.95 comfortably beat analyst estimates. The key driver for the stock's jump appeared to be the company's positive outlook. For 2026, Enovis forecasted full-year adjusted earnings per share to be in the range of $3.52 to $3.73. The midpoint of this forecast was significantly higher than what analysts had previously projected, signaling to investors that management expected strong profitability in the year ahead. This encouraging profit outlook overshadowed the slight revenue miss from the previous quarter.
Medical technology company Enovis Corporation (NYSE:ENOV) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 2.6% year on year to $575.8 million. The company’s full-year revenue guidance of $2.34 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.95 per share was 13.1% above analysts’ consensus estimates.
